When exploring the landscape of specialized biochemical research tools, the iRGD peptide sequence frequently emerges as a subject of significant interest. As someone who has spent considerable time analyzing the properties of various synthetic compounds, I have found the unique functionality of this specific sequence to be a fascinating example of molecular design.
Defining the iRGD Peptide Sequence
The iRGD peptide is fundamentally recognized as a 9-amino acid cyclic peptide. Its primary structure, often denoted in scientific literature as c(CRGDKGPDC), represents a sophisticated arrangement of amino acids that allows for highly specific interactions. When we look at the sequence: Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys, we see a precise configuration that includes a disulfide bridge between the first and ninth cysteine residues. This cyclization is cruci Enhancing Tumor Targeted Therapy: The Role of iRGD al for maintaining the structural integrity required for its intended biological recognition.
From my perspective, understanding that iRGD peptide is a 9-amino acid cyclic peptide is the first step in appreciating its role in research. The primary sequence of 1-11 (in specific experimental contexts) and the shorthand notation c[CRGDKGPDC] are standard references used by labs worldwide to identify this molecule.
Mechanisms of Action and Binding
The efficacy of this peptide lies in its ability to navigate complex cellular environments. It is well-documented that iRGD contains an Arg-Gly-Asp sequence, a motif that selectively binds to αvβ3 and αvβ5 integrins. These integrins are frequently overexpressed in specific vascular environments, making the peptide a subject of intense study regarding its targeting capabilities.
Furthermore, the iRGD peptide carrying drug cargo binds to integrin β3/β5 through this RGD motif. Once binding occurs, a secondary process is triggered. The iRGD peptide contains a CendR motif, which is a specific sequence located in the C-terminal that requires proteolytic processing. This mechanism is why iRGD, a cyclic 9-mer (CRGDKGPDC) CendR peptide, is often described as a tumor-penetrating peptide. The cleavage event allows the peptide to engage with neuropilin-1, facilitating deeper penetration into the target tissue.
Research Applications and Personal Observations
In my review of available data, the versatility of the iRGD peptide is apparent. Whether researchers are looking at an iRGD–PROTAC conjugation strategy or exploring how iRGD peptides (CRGDK/RGPD/EC) behave in vivo, the consistency of the amino acid sequence: CRGDKGPDC remains a cornerstone of the research.
When discussing iRGD's FAM-Cys-iRGD Cyclo RGD peptide, CRGDKGPDC utility, it is important to distinguish between the variants. Whi iRGD peptide(sequence: CRGDKGPDC) is a 9-amino acid cyclic peptide, and a molecular mimicry agent that was originally identified in an in vivo screening of le the standard is iRGD peptide CRGDKGPDC, researchers sometimes reference CRGDR/KGPDC to highlight the K-variant. Regardless of the specific variant, the RGD sequence remains the functional anchor for the ini iRGD peptide(sequence: CRGDKGPDC) is a 9-amino acid cyclic peptide, and a molecular mimicry agent that was originally identified in an in vivo screening of tial binding phase.
Summary of Specifications
For those tracking the technical details, the following parameters are generally associated with high-quality, research-grade material:
* Molecular A) Schematic illustration of the iRGD peptide for tumor cell Formula: C35H57N13O14S2
* Sequence: Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys (Cyclic)
* Characteristic: Disulfi Product Name.iRGD peptide; Sequence Shortening. c(CRGDKGPDC) (Disulfide bridge:Cys1-Cys9) ; Sequence. H-Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys-OH (Disulfide bridge Read more de bridge at Cys1-Cys9
* Role: Integrin-dependent penetration enhancer
The precision required to synthesize this peptide ensures that it performs as expected in controlled experimental setups. As someone who values the rigor of biochemical analysis, I find that the iRGD molecule stands out because of its elegant, multi-step mechanism—transitioning from an integrin-binding agent to a tissue-penetrating entity. It is a prime example of how small-scale molecular engineering can produce significant effects in a controlled laboratory environment.